Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Zhao Y, Wu D, Jiang D, Zhang X, Wu T, Cui J, Qian M, Zhao J, Oesterreich S, Sun W, Finkel T, Li G. A sequential methodology for the rapid identification and characterization of breast cancer associated functional SNPs. Nature communications. Forthcoming.
Kabraji S, Ni J, Sammons S, Li T, Van Swearingen AED, Wang Y, Pereslete A, Hsu L, DiPiro PJ, Lascola C, Moore H, Hughes M, Raghavendra AS, Gule-Monroe M, Murthy RK, Winer EP, Anders CK, Zhao JJ, Lin NU. Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases. Clin Cancer Res. 2023 Jan 4;29(1):174-182. doi: 10.1158/1078-0432.CCR-22-1138. PubMed PMID: 36074155; PubMed Central PMCID: PMC9811155.
Goel S, Bergholz JS, Zhao JJ. Targeting CDK4 and CDK6 in cancer. Nat Rev Cancer. 2022 Jun;22(6):356-372. doi: 10.1038/s41568-022-00456-3. Epub 2022 Mar 18. Review. PubMed PMID: 35304604; PubMed Central PMCID: PMC9149100.
Wang Q, Bergholz JS, Ding L, Lin Z, Kabraji SK, Hughes ME, He X, Xie S, Jiang T, Wang W, Zoeller JJ, Kim HJ, Roberts TM, Konstantinopoulos PA, Matulonis UA, Dillon DA, Winer EP, Lin NU, Zhao JJ. STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer. Nat Commun. 2022 May 31;13(1):3022. doi: 10.1038/s41467-022-30568-1. PubMed PMID: 35641483; PubMed Central PMCID: PMC9156717.
Chen P, Wang D, Wang Y, Zhang L, Wang Q, Liu L, Li J, Sun X, Ren M, Wang R, Fang Y, Zhao JJ, Zhang K. Maximizing TLR9 Activation in Cancer Immunotherapy with Dual-Adjuvanted Spherical Nucleic Acids. Nano Lett. 2022 May 25;22(10):4058-4066. doi: 10.1021/acs.nanolett.2c00723. Epub 2022 May 6. PubMed PMID: 35522597; PubMed Central PMCID: PMC9164000.
Gao X, Wang Y, Ribeiro CF, Manokaran C, Chang H, Von T, Rodrigues S, Cizmecioglu O, Jia S, Korpal M, Korn JM, Wang Z, Schmit F, Jiang L, Pagliarini R, Yang Y, Sethi I, Signoretti S, Yuan GC, Loda M, Zhao JJ, Roberts TM. Blocking PI3K p110β Attenuates Development of PTEN-Deficient Castration-Resistant Prostate Cancer. Mol Cancer Res. 2022 May 4;20(5):673-685. doi: 10.1158/1541-7786.MCR-21-0322. PubMed PMID: 35105671; PubMed Central PMCID: PMC9081176.
Ni J, Kabraji S, Xie S, Wang Y, Pan P, He X, Liu Z, Leone JP, Long HW, Brown MA, Winer EP, Dillon DAR, Lin NU, Zhao JJ. p16INK4A-deficiency predicts response to combined HER2 and CDK4/6 inhibition in HER2+ breast cancer brain metastases. Nat Commun. 2022 Mar 18;13(1):1473. doi: 10.1038/s41467-022-29081-2. PubMed PMID: 35304445; PubMed Central PMCID: PMC8933392.
Gaglia G, Kabraji S, Rammos D, Dai Y, Verma A, Wang S, Mills CE, Chung M, Bergholz JS, Coy S, Lin JR, Jeselsohn R, Metzger O, Winer EP, Dillon DA, Zhao JJ, Sorger PK, Santagata S. Temporal and spatial topography of cell proliferation in cancer. Nat Cell Biol. 2022 Mar;24(3):316-326. doi: 10.1038/s41556-022-00860-9. Epub 2022 Mar 15. PubMed PMID: 35292783; PubMed Central PMCID: PMC8959396.
Hu SH, He XD, Nie J, Hou JL, Wu J, Liu XY, Wei Y, Tang HR, Sun WX, Zhou SX, Yuan YY, An YP, Yan GQ, Lin Y, Lin PC, Zhao JJ, Ye ML, Zhao JY, Xu W, Zhao SM. Methylene-bridge tryptophan fatty acylation regulates PI3K-AKT signaling and glucose uptake. Cell Rep. 2022 Mar 15;38(11):110509. doi: 10.1016/j.celrep.2022.110509. PubMed PMID: 35294873; PubMed Central PMCID: PMC9396916.
Li Y, Pazyra-Murphy MF, Avizonis D, de Sá Tavares Russo M, Tang S, Chen CY, Hsueh YP, Bergholz JS, Jiang T, Zhao JJ, Zhu J, Ko KW, Milbrandt J, DiAntonio A, Segal RA. Sarm1 activation produces cADPR to increase intra-axonal Ca++ and promote axon degeneration in PIPN. J Cell Biol. 2022 Feb 7;221(2). doi: 10.1083/jcb.202106080. Epub 2021 Dec 22. PubMed PMID: 34935867; PubMed Central PMCID: PMC8704956.
Bergholz JS, Zhao JJ. How Compensatory Mechanisms and Adaptive Rewiring Have Shaped Our Understanding of Therapeutic Resistance in Cancer. Cancer Res. 2021 Dec 15;81(24):6074-6077. doi: 10.1158/0008-5472.CAN-21-3605. PubMed PMID: 34911779; PubMed Central PMCID: PMC9033251.
Berghausen EM, Janssen W, Vantler M, Gnatzy-Feik LL, Krause M, Behringer A, Joseph C, Zierden M, Freyhaus HT, Klinke A, Baldus S, Alcazar MA, Savai R, Pullamsetti SS, Wong DW, Boor P, Zhao JJ, Schermuly RT, Rosenkranz S. Disrupted PI3K subunit p110α signaling protects against pulmonary hypertension and reverses established disease in rodents. J Clin Invest. 2021 Oct 1;131(19). doi: 10.1172/JCI136939. PubMed PMID: 34596056; PubMed Central PMCID: PMC8483754.
Wang Q, Tao C, Hannan A, Yoon S, Min X, Peregrin J, Qu X, Li H, Yu H, Zhao J, Zhang X. Lacrimal gland budding requires PI3K-dependent suppression of EGF signaling. Sci Adv. 2021 Jun;7(27). doi: 10.1126/sciadv.abf1068. Print 2021 Jun. PubMed PMID: 34193412; PubMed Central PMCID: PMC8245041.
Xie S, Ni J, Guo H, Luu V, Wang Y, Zhao JJ, Roberts TM. The role of the PIK3CA gene in the development and aging of the brain. Sci Rep. 2021 Jan 11;11(1):291. doi: 10.1038/s41598-020-79416-6. PubMed PMID: 33431926; PubMed Central PMCID: PMC7801510.
Watt AC, Cejas P, DeCristo MJ, Metzger-Filho O, Lam EYN, Qiu X, BrinJones H, Kesten N, Coulson R, Font-Tello A, Lim K, Vadhi R, Daniels VW, Montero J, Taing L, Meyer CA, Gilan O, Bell CC, Korthauer KD, Giambartolomei C, Pasaniuc B, Seo JH, Freedman ML, Ma C, Ellis MJ, Krop I, Winer E, Letai A, Brown M, Dawson MA, Long HW, Zhao JJ, Goel S. CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity. Nat Cancer. 2021 Jan;2(1):34-48. doi: 10.1038/s43018-020-00135-y. Epub 2020 Nov 9. PubMed PMID: 33997789; PubMed Central PMCID: PMC8115221.
Bergholz JS, Wang Q, Kabraji S, Zhao JJ. Integrating Immunotherapy and Targeted Therapy in Cancer Treatment: Mechanistic Insights and Clinical Implications. Clin Cancer Res. 2020 Nov 1;26(21):5557-5566. doi: 10.1158/1078-0432.CCR-19-2300. Epub 2020 Jun 23. Review. PubMed PMID: 32576627; PubMed Central PMCID: PMC7641965.
Xie S, Ni J, McFaline-Figueroa JR, Wang Y, Bronson RT, Ligon KL, Wen PY, Roberts TM, Zhao JJ. Divergent Roles of PI3K Isoforms in PTEN-Deficient Glioblastomas. Cell Rep. 2020 Sep 29;32(13):108196. doi: 10.1016/j.celrep.2020.108196. PubMed PMID: 32997991; PubMed Central PMCID: PMC7571617.
Spangle JM, Von T, Pavlick DC, Khotimsky A, Zhao JJ, Roberts TM. PIK3CA C-terminal frameshift mutations are novel oncogenic events that sensitize tumors to PI3K-α inhibition. Proc Natl Acad Sci U S A. 2020 Sep 29;117(39):24427-24433. doi: 10.1073/pnas.2000060117. Epub 2020 Sep 14. PubMed PMID: 32929011; PubMed Central PMCID: PMC7533832.
Ngo B, Kim E, Osorio-Vasquez V, Doll S, Bustraan S, Liang RJ, Luengo A, Davidson SM, Ali A, Ferraro GB, Fischer GM, Eskandari R, Kang DS, Ni J, Plasger A, Rajasekhar VK, Kastenhuber ER, Bacha S, Sriram RK, Stein BD, Bakhoum SF, Snuderl M, Cotzia P, Healey JH, Mainolfi N, Suri V, Friedman A, Manfredi M, Sabatini DM, Jones DR, Yu M, Zhao JJ, Jain RK, Keshari KR, Davies MA, Vander Heiden MG, Hernando E, Mann M, Cantley LC, Pacold ME. Limited Environmental Serine and Glycine Confer Brain Metastasis Sensitivity to PHGDH Inhibition. Cancer Discov. 2020 Sep;10(9):1352-1373. doi: 10.1158/2159-8290.CD-19-1228. Epub 2020 Jun 22. PubMed PMID: 32571778; PubMed Central PMCID: PMC7483776.
Fassl A, Brain C, Abu-Remaileh M, Stukan I, Butter D, Stepien P, Feit AS, Bergholz J, Michowski W, Otto T, Sheng Q, Loo A, Michael W, Tiedt R, DeAngelis C, Schiff R, Jiang B, Jovanovic B, Nowak K, Ericsson M, Cameron M, Gray N, Dillon D, Zhao JJ, Sabatini DM, Jeselsohn R, Brown M, Polyak K, Sicinski P. Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition. Sci Adv. 2020 Jun;6(25):eabb2210. doi: 10.1126/sciadv.abb2210. eCollection 2020 Jun. PubMed PMID: 32704543; PubMed Central PMCID: PMC7360435.
Bhola PD, Ahmed E, Guerriero JL, Sicinska E, Su E, Lavrova E, Ni J, Chipashvili O, Hagan T, Pioso MS, McQueeney K, Ng K, Aguirre AJ, Cleary JM, Cocozziello D, Sotayo A, Ryan J, Zhao JJ, Letai A. High-throughput dynamic BH3 profiling may quickly and accurately predict effective therapies in solid tumors. Sci Signal. 2020 Jun 16;13(636). doi: 10.1126/scisignal.aay1451. PubMed PMID: 32546544; PubMed Central PMCID: PMC8023011.
Sun B, Mason S, Wilson RC, Hazard SE, Wang Y, Fang R, Wang Q, Yeh ES, Yang M, Roberts TM, Zhao JJ, Wang Q. Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers. Oncogene. 2020 Jan;39(1):50-63. doi: 10.1038/s41388-019-0953-9. Epub 2019 Aug 28. PubMed PMID: 31462705; PubMed Central PMCID: PMC6937212.
Hemmati S, Sinclair T, Tong M, Bartholdy B, Okabe RO, Ames K, Ostrodka L, Haque T, Kaur I, Mills TS, Agarwal A, Pietras EM, Zhao JJ, Roberts TM, Gritsman K. PI3 kinase alpha and delta promote hematopoietic stem cell activation. JCI Insight. 2019 May 23;5. doi: 10.1172/jci.insight.125832. PubMed PMID: 31120863; PubMed Central PMCID: PMC6629136.
Wen PY, Touat M, Alexander BM, Mellinghoff IK, Ramkissoon S, McCluskey CS, Pelton K, Haidar S, Basu SS, Gaffey SC, Brown LE, Martinez-Ledesma JE, Wu S, Kim J, Wei W, Park MA, Huse JT, Kuhn JG, Rinne ML, Colman H, Agar NYR, Omuro AM, DeAngelis LM, Gilbert MR, de Groot JF, Cloughesy TF, Chi AS, Roberts TM, Zhao JJ, Lee EQ, Nayak L, Heath JR, Horky LL, Batchelor TT, Beroukhim R, Chang SM, Ligon AH, Dunn IF, Koul D, Young GS, Prados MD, Reardon DA, Yung WKA, Ligon KL. Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. J Clin Oncol. 2019 Mar 20;37(9):741-750. doi: 10.1200/JCO.18.01207. Epub 2019 Feb 4. PubMed PMID: 30715997; PubMed Central PMCID: PMC6553812.
Liu Z, Wang Y, Kabraji S, Xie S, Pan P, Liu Z, Ni J, Zhao JJ. Improving orthotopic mouse models of patient-derived breast cancer brain metastases by a modified intracarotid injection method. Sci Rep. 2019 Jan 24;9(1):622. doi: 10.1038/s41598-018-36874-3. PubMed PMID: 30679540; PubMed Central PMCID: PMC6346002.
Li BB, Qian C, Roberts TM, Zhao JJ. Targeted Profiling of RNA Translation. Curr Protoc Mol Biol. 2019 Jan;125(1):e71. doi: 10.1002/cpmb.71. Epub 2018 Oct 22. PubMed PMID: 30346115; PubMed Central PMCID: PMC6326074.
Ding L, Kim HJ, Wang Q, Kearns M, Jiang T, Ohlson CE, Li BB, Xie S, Liu JF, Stover EH, Howitt BE, Bronson RT, Lazo S, Roberts TM, Freeman GJ, Konstantinopoulos PA, Matulonis UA, Zhao JJ. PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer. Cell Rep. 2018 Dec 11;25(11):2972-2980.e5. doi: 10.1016/j.celrep.2018.11.054. PubMed PMID: 30540933; PubMed Central PMCID: PMC6366450.
Wang Y, Li BB, Li J, Roberts TM, Zhao JJ. A Conditional Dependency on MELK for the Proliferation of Triple-Negative Breast Cancer Cells. iScience. 2018 Nov 30;9:149-160. doi: 10.1016/j.isci.2018.10.015. Epub 2018 Oct 18. PubMed PMID: 30391850; PubMed Central PMCID: PMC6215964.
Goel S, DeCristo MJ, McAllister SS, Zhao JJ. CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest. Trends Cell Biol. 2018 Nov;28(11):911-925. doi: 10.1016/j.tcb.2018.07.002. Epub 2018 Jul 27. Review. PubMed PMID: 30061045; PubMed Central PMCID: PMC6689321.
Pan P, Chen J, Li X, Li M, Yu H, Zhao JJ, Ni J, Wang X, Sun H, Tian S, Zhu F, Liu F, Huang Y, Hou T. Structure-Based Drug Design and Identification of H2O-Soluble and Low Toxic Hexacyclic Camptothecin Derivatives with Improved Efficacy in Cancer and Lethal Inflammation Models in Vivo. J Med Chem. 2018 Oct 11;61(19):8613-8624. doi: 10.1021/acs.jmedchem.8b00498. Epub 2018 Sep 27. PubMed PMID: 30227711; PubMed Central PMCID: PMC6668024.
Li AG, Murphy EC, Culhane AC, Powell E, Wang H, Bronson RT, Von T, Giobbie-Hurder A, Gelman RS, Briggs KJ, Piwnica-Worms H, Zhao JJ, Kung AL, Kaelin WG Jr, Livingston DM. BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1α activation. Proc Natl Acad Sci U S A. 2018 Oct 9;115(41):E9600-E9609. doi: 10.1073/pnas.1807112115. Epub 2018 Sep 25. PubMed PMID: 30254159; PubMed Central PMCID: PMC6187201.
Li BB, Qian C, Gameiro PA, Liu CC, Jiang T, Roberts TM, Struhl K, Zhao JJ. Targeted profiling of RNA translation reveals mTOR-4EBP1/2-independent translation regulation of mRNAs encoding ribosomal proteins. Proc Natl Acad Sci U S A. 2018 Oct 2;115(40):E9325-E9332. doi: 10.1073/pnas.1805782115. Epub 2018 Sep 17. PubMed PMID: 30224479; PubMed Central PMCID: PMC6176620.
Li J, Choi PS, Chaffer CL, Labella K, Hwang JH, Giacomelli AO, Kim JW, Ilic N, Doench JG, Ly SH, Dai C, Hagel K, Hong AL, Gjoerup O, Goel S, Ge JY, Root DE, Zhao JJ, Brooks AN, Weinberg RA, Hahn WC. An alternative splicing switch in FLNB promotes the mesenchymal cell state in human breast cancer. Elife. 2018 Jul 30;7. doi: 10.7554/eLife.37184. PubMed PMID: 30059005; PubMed Central PMCID: PMC6103745.
Sun B, Wang G, Liu H, Liu P, Twal WO, Cheung H, Carroll SL, Ethier SP, Mevers EE, Clardy J, Roberts T, Chen C, Li Q, Wang L, Yang M, Zhao JJ, Wang Q. Oridonin inhibits aberrant AKT activation in breast cancer. Oncotarget. 2018 May 8;9(35):23878-23889. doi: 10.18632/oncotarget.24378. eCollection 2018 May 8. PubMed PMID: 29844859; PubMed Central PMCID: PMC5963618.
Bergholz JS, Roberts TM, Zhao JJ. Isoform-Selective Phosphatidylinositol 3-Kinase Inhibition in Cancer. J Clin Oncol. 2018 May 1;36(13):1339-1342. doi: 10.1200/JCO.2017.77.0891. Epub 2018 Mar 8. PubMed PMID: 29517943.
Kabraji S, Ni J, Lin NU, Xie S, Winer EP, Zhao JJ. Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain?. Clin Cancer Res. 2018 Apr 15;24(8):1795-1804. doi: 10.1158/1078-0432.CCR-17-3351. Epub 2018 Feb 6. PubMed PMID: 29437794; PubMed Central PMCID: PMC5899637.
Jeselsohn R, Bergholz JS, Pun M, Cornwell M, Liu W, Nardone A, Xiao T, Li W, Qiu X, Buchwalter G, Feiglin A, Abell-Hart K, Fei T, Rao P, Long H, Kwiatkowski N, Zhang T, Gray N, Melchers D, Houtman R, Liu XS, Cohen O, Wagle N, Winer EP, Zhao J, Brown M. Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations. Cancer Cell. 2018 Feb 12;33(2):173-186.e5. doi: 10.1016/j.ccell.2018.01.004. PubMed PMID: 29438694; PubMed Central PMCID: PMC5813700.
Simond AM, Rao T, Zuo D, Zhao JJ, Muller WJ. ErbB2-positive mammary tumors can escape PI3K-p110α loss through downregulation of the Pten tumor suppressor. Oncogene. 2017 Oct 26;36(43):6059-6066. doi: 10.1038/onc.2017.264. Epub 2017 Aug 7. PubMed PMID: 28783168; PubMed Central PMCID: PMC5808977.
Venkatesh HS, Tam LT, Woo PJ, Lennon J, Nagaraja S, Gillespie SM, Ni J, Duveau DY, Morris PJ, Zhao JJ, Thomas CJ, Monje M. Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma. Nature. 2017 Sep 28;549(7673):533-537. doi: 10.1038/nature24014. Epub 2017 Sep 20. PubMed PMID: 28959975; PubMed Central PMCID: PMC5891832.
Huang HT, Seo HS, Zhang T, Wang Y, Jiang B, Li Q, Buckley DL, Nabet B, Roberts JM, Paulk J, Dastjerdi S, Winter GE, McLauchlan H, Moran J, Bradner JE, Eck MJ, Dhe-Paganon S, Zhao JJ, Gray NS. MELK is not necessary for the proliferation of basal-like breast cancer cells. Elife. 2017 Sep 19;6. doi: 10.7554/eLife.26693. PubMed PMID: 28926338; PubMed Central PMCID: PMC5605198.
Goel S, DeCristo MJ, Watt AC, BrinJones H, Sceneay J, Li BB, Khan N, Ubellacker JM, Xie S, Metzger-Filho O, Hoog J, Ellis MJ, Ma CX, Ramm S, Krop IE, Winer EP, Roberts TM, Kim HJ, McAllister SS, Zhao JJ. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017 Aug 24;548(7668):471-475. doi: 10.1038/nature23465. Epub 2017 Aug 16. PubMed PMID: 28813415; PubMed Central PMCID: PMC5570667.
Spangle JM, Roberts TM, Zhao JJ. The emerging role of PI3K/AKT-mediated epigenetic regulation in cancer. Biochim Biophys Acta Rev Cancer. 2017 Aug;1868(1):123-131. doi: 10.1016/j.bbcan.2017.03.002. Epub 2017 Mar 14. Review. PubMed PMID: 28315368; PubMed Central PMCID: PMC5548615.
Zhang J, Gao X, Schmit F, Adelmant G, Eck MJ, Marto JA, Zhao JJ, Roberts TM. CRKL Mediates p110β-Dependent PI3K Signaling in PTEN-Deficient Cancer Cells. Cell Rep. 2017 Jul 18;20(3):549-557. doi: 10.1016/j.celrep.2017.06.054. PubMed PMID: 28723560; PubMed Central PMCID: PMC5704918.
Thorpe LM, Spangle JM, Ohlson CE, Cheng H, Roberts TM, Cantley LC, Zhao JJ. PI3K-p110α mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85α. Proc Natl Acad Sci U S A. 2017 Jul 3;114(27):7095-7100. doi: 10.1073/pnas.1704706114. Epub 2017 Jun 19. PubMed PMID: 28630349; PubMed Central PMCID: PMC5502636.
Hydbring P, Wang Y, Fassl A, Li X, Matia V, Otto T, Choi YJ, Sweeney KE, Suski JM, Yin H, Bogorad RL, Goel S, Yuzugullu H, Kauffman KJ, Yang J, Jin C, Li Y, Floris D, Swanson R, Ng K, Sicinska E, Anders L, Zhao JJ, Polyak K, Anderson DG, Li C, Sicinski P. Cell-Cycle-Targeting MicroRNAs as Therapeutic Tools against Refractory Cancers. Cancer Cell. 2017 Apr 10;31(4):576-590.e8. doi: 10.1016/j.ccell.2017.03.004. PubMed PMID: 28399412; PubMed Central PMCID: PMC5425285.
Ni J, Xie S, Ramkissoon SH, Luu V, Sun Y, Bandopadhayay P, Beroukhim R, Roberts TM, Stiles CD, Segal RA, Ligon KL, Hahn WC, Zhao JJ. Tyrosine receptor kinase B is a drug target in astrocytomas. Neuro Oncol. 2017 Jan;19(1):22-30. doi: 10.1093/neuonc/now139. Epub 2016 Jul 10. PubMed PMID: 27402815; PubMed Central PMCID: PMC5193024.
Mathew G, Hannan A, Hertzler-Schaefer K, Wang F, Feng GS, Zhong J, Zhao JJ, Downward J, Zhang X. Targeting of Ras-mediated FGF signaling suppresses Pten-deficient skin tumor. Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):13156-13161. doi: 10.1073/pnas.1604450113. Epub 2016 Oct 31. PubMed PMID: 27799550; PubMed Central PMCID: PMC5135310.
Ferguson FM, Ni J, Zhang T, Tesar B, Sim T, Kim ND, Deng X, Brown JR, Zhao JJ, Gray NS. Discovery of a Series of 5,11-Dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-ones as Selective PI3K-δ/γ Inhibitors. ACS Med Chem Lett. 2016 Oct 13;7(10):908-912. doi: 10.1021/acsmedchemlett.6b00209. eCollection 2016 Oct 13. PubMed PMID: 27774127; PubMed Central PMCID: PMC5066161.
Cizmecioglu O, Ni J, Xie S, Zhao JJ, Roberts TM. Rac1-mediated membrane raft localization of PI3K/p110β is required for its activation by GPCRs or PTEN loss. Elife. 2016 Oct 4;5. doi: 10.7554/eLife.17635. PubMed PMID: 27700986; PubMed Central PMCID: PMC5050018.
Yuzugullu H, Von T, Thorpe LM, Walker SR, Roberts TM, Frank DA, Zhao JJ. NTRK2 activation cooperates with PTEN deficiency in T-ALL through activation of both the PI3K-AKT and JAK-STAT3 pathways. Cell Discov. 2016;2:16030. doi: 10.1038/celldisc.2016.30. eCollection 2016. PubMed PMID: 27672444; PubMed Central PMCID: PMC5029543.
What would you like to do?